טרימבו 100/6/12.5 - Trimbow 100/6/12.5

× ×ª×× × ×ª×¨××¤×

××¡× ×××¨××××ª

××× ×× ×× × ××¡×¤××

××¨×××× 200/6/12.5 - Trimbow 200/6/12.5

×§×××¦× ×¤×¨××§××××××ª (ATC4)

R03AL
Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids

××¨××× ×¤×¢×× (ATC5)

Beclometasone dipropionate 100 MCG/ACTUATION ââR03AL09
Formoterol fumarate dihydrate 6 MCG/ACTUATION âR03AL09
Glycopyrronium bromide 12.5 MCG/ACTUATION âR03AL09

×¦××¨×ª ××ª×

×©×××¤× - INHALATION

×¦××¨×ª ××× ××

PRESSURISED SOLUTION
××× ××¢×ª ××× ×× ××ª×¨ ×× ××¨×¢×× ××© ××××× ××ª ××ª×¨××¤× ×××ª×× ×××× ×× ××××××¥ ××¤× ×©×××¤××¢ ××¢××× ××¦×¨××

××ª××××

COPD Maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist or a combination of a long-acting beta2-agonist and a long-acting muscarinic antagonist. Asthma Maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and medium dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year.â¦

× ×ª×× × ××¡×

×ª××¨×× ××××× ××¡×

16/01/2019

××××××ª ××¡×

×ª×¨××¤× ××××××ª ××¨××©×× ×¢'× ×¨××¤× ××××× ×× ××××× ×××¨×ª

××ª×××× ××¡×

××ª××××	×ª××¨×× ×××××	×ª××× ×§××× ×	××¦× ××××
××××ª ×¨××××ª ××¡×××ª××ª ××¨×× ××ª (COPD â Chronic Obstructive Pulmonary Disease) ×××××× ×¢× FEV1 ×©××× ×× × ××× ×-60% ×××¦× ××¨×× ×; ×ª××××ª ××××¤×× ××ª×¨××¤× ×ª××¢×©× ××¤× ××¨×©× ×©× ×¨××¤× ××××× ××¨×¤×××ª ×¨××××ª	16/01/2019	×¨×¤×××ª ×¨××××ª	COPD, ××××ª ×¨××××ª ××¡×××ª××ª ××¨×× ××ª, Chrnoic obstructive pulmonary disease
××××ª ×¨××××ª ××¡×××ª××ª ××¨×× ××ª (COPD â Chronic Obstructive Pulmonary Disease).	17/03/2024	×¨×¤×××ª ×¨××××ª	××××ª ×¨××××ª ××¡×××ª××ª ××¨×× ××ª, COPD â Chronic Obstructive Pulmonary Disease
×××¤×× ××××§× ×××××× ××××¨×× ×¢× ××¡××× ×©×¢×× ×× ×¢× ×× ×××: 1. ××××¤××× ×××× ×× ×××× ××××¤×× ××©××× ×©× ×§××¨×××§××¡××¨×××××× ××©×××¤× (ICS) ××ª×¨××¤××ª ×××©×¤××ª ×-Long acting beta agonists (LABA). 2. ××× ××¤×××ª ××××¨× (exacerbation) ×××ª ×©× ××××ª× ××©× × ××××¨×× × ×©××××× ×××¤×× ××¡××¨×××××× ×¡××¡×××××.	17/03/2024	×¨×¤×××ª ×¨××××ª	××¡×××, Asthma

×©××××© ××¡×

××¡××¨×ª ××××× ××¡×

××ª×¨××¤× ×ª×× ×ª× ××××¤×× ×××§×¨×× ××××:

×. ××××ª ×¨××××ª ××¡×××ª××ª ××¨×× ××ª (COPD â Chronic Obstructive Pulmonary Disease).

×. ×××¤×× ××××§× ×××××× ××××¨×× ×¢× ××¡××× ×©×¢×× ×× ×¢× ×× ×××:

1. ××××¤××× ×××× ×× ×××× ××××¤×× ××©××× ×©× ×§××¨×××§××¡××¨×××××× ××©×××¤× (ICS) ××ª×¨××¤××ª ×××©×¤××ª ×-Long acting beta agonists (LABA).

2. ××× ××¤×××ª ××××¨× (exacerbation) ×××ª ×©× ××××ª× ××©× × ××××¨×× × ×©××××× ×××¤×× ××¡××¨×××××× ×¡××¡×××××.

××ª×××ª ××× ××

Posology and method of administration

××ª×××××ª × ××

Contraindications

×ª××¤×¢××ª ×××××

Undesirable effects

×ª×××××ª ××× ×ª×¨××¤×ª×××ª

Interaction with other medicinal products and other forms of interaction

Pregnancy and Lactation

×¤×¨××§×××× ×××§×

Pharmacodynamic Properties

×¤×¨××§××§×× ×××§×

Pharmacokinetic Properties

×¢××× ××¨××¤× ×××××¨××ª ××¢×××

×¢××× ××¨××¤× 30.11.2024

××××¨× ××¢××× 15.10.2022

×¢××× ××¦×¨××	Â ×¢××× ××¦×¨×× ×¢××¨××ª 30.11.2024 ×¢××× ××¦×¨×× ×× ××××ª - Patient information leaflet â30.11.2024 ×¢××× ××¦×¨×× ×¢×¨×××ª - ÙØ´Ø±Ø© ÙÙÙØ³ØªÙÙÙ Ø¨Ø§ÙÙØºØ© Ø§ÙØ¹Ø±Ø¨ÙØ© 30.11.2024

×¢×¨××× ×××××§××¨×¤×××	×¢×¨××× ×§×©××¨×× ×××××§××¨×¤×××
××¨×××× 100/6/12.5 ×××××¨ ××©×¨× ×××¨××××ª

×××¤××© ××××¨××	××××¨×× ×-PubMed
××××¢ ××¨×©×ª	RxList WebMD Drugs.com
×©× ××¦×¨×	CHIESI FARMACEUTICI S.P.A, ITALY
×©× ××¢× ××¨××©××	KAMADA LTD, ISRAEL
×¨××©×××	×ª××¨×× ×××©×: 5/2019. ×¨××©××× ××ª××¨××:
×ª××¨×× ×¢×××× ×××¨××	13/05/2025

×ª××× ×ª ××¨×××

×ª××× ×ª ××¨×××

השינוי האחרון נעשה בֹ־13 במאי 2025 ב־07:33

טרימבו 100/6/12.5 - Trimbow 100/6/12.5

ויקיתרופות